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Summary Irinotecan hydrochloride (CPT-11) shows marked anti-tumour activity alone and in combination with cisplatin in non-small-cell lung
cancer (NSCLC). It is necessary to investigate combined-modality therapy including novel effective anti-cancer agents to improve long-term
survival of patients with unresectable stage Ill NSCLC. A phase I/ll study of concurrent chemoradiotherapy with CPT-11 and cisplatin was
conducted to determine the maximum tolerated dose (MTD) and efficacy in this group of patients. Thirteen previously untreated patients with
unresectable stage IIIA/B NSCLC were enrolled and efficacy and toxicity was evaluated in 12 of them; one patient was ineligible.
Chemotherapy was repeated every 4 weeks forthree courses. Radiation therapy was started on day 2 ofthe first course of chemotherapy and
60 Gy in 30 fractions was given over 6 weeks. Four of six patients enrolled at level 1 completed the scheduled treatment. Another two
received only one and two courses of chemotherapy as a result of persistent leucopenia and neutropenic fever respectively. Three of six
patients given level 2 therapy completed the scheduled treatment. Another three received only one and two courses of chemotherapy, two
refused treatment because of diarrhoea and one died of pneumonia. Radiation therapy was inadequate in these three patients. As the CPT-
11 dose intensity in this trial was low, because of the necessity of omitting CPT-11 administration on days 8 and/or 15 as a result of leucopenia
or diarrhoea, and the low radiation therapy completion rate, the trial was discontinued at level 2. Five patients at level 1 and three at level 2
showed partial responses, an overall response rate of 67%. Although neither MTD nor dose-limiting toxicity could be identified, chemotherapy
with CPT-11 and cisplatin plus concurrent radiation therapy was deemed unacceptable. We are now conducting a phase I/Il study of
chemotherapy using CPT-11 as a single agent in combination with radiation therapy.
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Approximately 25-30% ofnon-small cell lung cancer (NSCLC) is
already unresectable stage III disease by the time it is diagnosed
and, therefore, about 7000 such patients are seen in Japan per year.
Traditionally, the standard treatment is radiation therapy, but the 5-
year survival rate is 10% or less in patients treated with radiation
therapy alone and the majority ofpatients experience extrathoracic
recurrence (Perez et al, 1987). It is important to control distant
metastases, as well as local tumours, in order to improve long-term
survival. The efficacy of chemotherapy in such patients has long
been a controversial issue. Recently, several randomized trials
(Dillman et al, 1990, 1996; Le Chevalier et al, 1991; Sause et al,
1995) and meta-analysis (Non-small Cell Lung Cancer
Collaborative Group, 1995) showed that chemotherapy followed
by radiation therapy was more effective than radiation therapy
alone. However, survival was still only prolonged by several
months and it is necessary to investigate combined-modality
therapy, including novel effective anti-cancer agents, and to estab-
lish the optimal timing and fractionation ofradiation therapy.
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Irinotecan hydrochloride (CPT-11), a new derivative ofcampto-
thecin, is one ofthe most active drugs against NSCLC (Fukuoka et
al, 1992; Douillard et al, 1995; Baker et al, 1997). Furthermore,
the addition of cisplatin to CPT-11 has been reported to result in
synergistic cytotoxicity in preclinical models (Pei et al, 1997).
Phase 1/11 studies of CPT-11 combined with cisplatin in patients
with advanced NSCLC demonstrated a high response rate
(31-48%) and a promising median survival (44 weeks) (Masuda et
al, 1992; Nakagawa et al, 1993; DeVore et al, 1997). The adminis-
tration of concomitant chemoradiotherapy has been shown to
increase local and regional control of locally advanced NSCLC
(Schaake-Koning et al, 1992). We considered that combined CPT-
11 and cisplatin with concurrent radiation therapy could produce a
high response rate and better survival outcome if it could be deliv-
ered at full dose. To our knowledge, no clinical studies on the
concurrent use of CPT-11 and radiation therapy have been
performed. Based on this idea the Japan Clinical Oncology Group
(JCOG) initiated a dose-finding study of this combined modality.
This study consisted of two phases: the first involved examining
the optimal doses of CPT-11 and cisplatin plus concurrent radia-
tion therapy by administering escalating doses of CPT-11 and
cisplatin; and in the second, the anti-tumour effects and safety of
this regimen were to be investigated using the recommended doses
ofCPT-11 and cisplating established in phase I.
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MATERIALS AND METHODS
Patient selection
Patients with previously untreated NSCLC, diagnosed definitively
histologically or cytologically, participated in this study. Patients
were considered eligible if: they had unresectable stage IIIA or
IIIB disease that was measurable, radical radiation therapy with a
specified radiation field was possible, they were < 75 years and
had an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 or 1.
Before initiating treatment, a full medical history was obtained,
physical examination was performed and definitive disease staging
was carried out based on the following: complete blood cell count,
serum chemistry, serum electrolytes, creatinine clearance, urinalysis,
tumour markers, pulmonary function test, electrocardiogram (ECG),
blood gas analysis, chest radiology, computerized tomography
(chest, brain, abdomen), bronchoscopy and bone scan. All patients
enrolled were required to have adequate organ function, i.e. WBC 2
4000 pi-', haemoglobin 2 10 g dl', platelet count > 10 x 104 t1l',
total bilirubin < 1.5 mg dl-1, GOT/GPT < normal value x 2, creati-
nine < 1.5 mg dl-', creatinine clearance 60 ml min-' and po2 >70 T.
Patients with pleural effusion, apparent pericardial effusion, a history
of malignancy within 5 years of entering the study. serious heart
disease, uncontrollable diabetes, uncontrollable hypertension,
chronic pulmonary disease that would make radiation therapy diffi-
cult and/or serious concomitant infection were excluded. All patients
gave written informed consent before enrolment. The study was
approved by the Clinical Trial Review Committee ofJCOG and the
ethics committee ofeach collaborating centre.
Treatment plan
Eligible patients started treatment within 1 week of enrolment.
Three courses of chemotherapy (CPT- 11, days 1, 8 and 15;
cisplatin, day 1) were repeated at 4-week intervals and concurrent
radiation therapy was given once daily (2 Gy, 5 days per week
from day 2 of the first course of chemotherapy). The total dose
was intended to be 60 Gy in 30 fractions over a period of 6 weeks.
Chemotherapy
CPT- II was dissolved in 250 ml of 5% w/v glucose and adminis-
tered i.v. over 90 min followed 2 h later by cisplatin, which was
administered i.v. over 60 min on day 1. The participating
researchers at each institution were allowed to decide how much
fluid replacement and what antiemetic therapy should be adminis-
tered, but adequate amounts of parenteral fluid and diuretics were
to be given in order to prevent the renal toxicity ofcisplatin.
Dose escalation schedule
Dose escalation was planned in three levels, i.e. 40 mg m-'CPT- 11
and 60 mg m-2 cisplatin at level 1, 60 mg m-2 CPT-11 and
60 mg m-2 cisplatin at level 2 and 60 mg m-2 CPT- 11 and
80 mg m- cisplatin at level 3. The initial dose of cisplatin was
60 mg m-2, 75% of its recommended dose in combination
chemotherapy. CPT- 11 was initially given at a dose of 40 mg /mr,
40% of its recommended dose as single agent (Negoro et al, 1991)
and 66% of that recommended in combination with cisplatin
(Masuda et al, 1992).
Six patients were enrolled at each level and evaluated on
completion of the first course of chemotherapy and radiation
therapy. If three of six patients had to discontinue treatment as a
result of toxicity, dose escalation was to be discontinued, but if
only two of six patients discontinued, it was to be continued to the
next level. The doses of CPT- II and cisplatin to be used for the
phase II study were to be determined by examining carefully the
toxicities resulting from second and third courses in particular, as
well as the first, and the dose intensities ofthe two agents.
Radiation therapy
A3- to 10-MeV linear accelerator with two posterioanterior
opposed beams was used. The area ofthe lung field included in the
radiation field was to be no greater than half the area of the unilat-
eral lung. The radiation field was established 1.5 cm beyond the
margin of the primary lesion and included the ispilateral hilar and
mediastinal nodes. If metastasis to the supraclavicular node was
found, this node was also to be included in the radiation field.
Reduction of the radiation field was allowed, providing that at
least 40 Gy had been administered and the researchers at each




CPT- Il was omitted if the WBC count was <3000pl-t' and/or
platelet count was 75 x 103/t1-I on day 8 (or day 15) of
chemotherapy. If the WBC count was < 2000 pl-t or neutrophil
count was < 1000 tI-' granulocyte colony-stimulating factor (G-
CSF) was administered subcutaneously until recovery. The next
course of chemotherapy was started after confirmation of WBC
recovery to 2 3000 .tl-' and platelets to > 75 x 10:3 tl-'. If no
recovery occurred, even after postponing the start of
chemotherapy for . 3 weeks, chemotherapy was to be discon-
tinued. Ifgrade 4 leucopenia or neutropenia continued for 2 4 days
or grade 4 thrombocytopenia occurred during the previous
chemotherapy course, the CPT-11 dose was reduced to 75% ofthat



























aAccording to the Eastern Cooperative Oncology Group.
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Table 2 Dose escalation scheme and treatment given to patients at each dose level
Dose (mg m2)
CPT-11 Cisplatin No. of No. of No. of % of TRT dose
Level day 1, 8,15 day 1 patients courses omitteda ADDIb >60 Gy
1 40 60 6 15 11 72 6
2 60 60 6 13 12 63 2
3 60 80 -
aNo. of times that necessitated omitting CPT-11 administration on day 8 and/or day 15 because of leucopenia or diarrhoea. bPer cent of actually delivered dose
intensity of CPT-11.
Table 3 Haematological toxicity at each dose level
JCOG toxicity criteria
No. of patients/ WBC grade Platelet grade Anaemia grade G-CSF
Level no. of courses No. of courses
3 4 3 3
1 6/15 6/9 0/0 0/0 0/0 8
2 6/13 1/5 2/2 2/2 2/2 10
JCOG, Japan Clinical Oncology Group; G-CSF, granulocyte colony-stimulating factor.
specified for the next treatment course. If grade 4 haematological
toxicity occurred during radiation therapy, radiation therapy was
interrupted and restarted after recovery to grade 3 or less.
Diarrhoea
If grade 2 or greater diarrhoea and/or abdominal pain occurred,
CPT-I1 was interrupted, and the next course was only started ifthe
diarrhoea had resolved. If grade 3 or greater diarrhoea and/or
abdominal pain had occurred during the previous chemotherapy
course, the next CPT- 11 dose was reduced to 75% ofthat specified.
Oesophagitis
If grade 3 or greater oesophagitis occurred, radiation therapy was
interrupted and restarted after recovery to grade 2 or less. If the
severity of oesophagitis did not decrease to grade 2 or less even
after 2 or more weeks, radiation therapy was discontinued.
Pulmonary toxicity
If po, fell to 10 torr or lower, both radiation therapy and
chemotherapy were interrupted and restarted as soon as possible
after recovery. Ifdiffuse interstitial pneumonia occurred, treatment
was to be discontinued and steroid therapy instituted.
Fever
If a patient had a fever of38°C or higher, chemotherapy and radia-
tion therapy were postponed until the fever subsided.
Other toxicities (excluding nausea/vomiting andalopecia)
If other grade 2 or greater non-haematological toxicity occurred,
treatment was postponed until recovery. If it was considered diffi-
cult to continue treatment even though toxicity was grade 2 or less,
treatment was postponed until recovery. If treatment could not be
restarted even after 2 or more weeks, treatment was discontinued.
Treatment duration was intended to be within 16 weeks for
chemotherapy and within 12 weeks forradiation therapy. Iftreatment
was not completed within these time periods, it was discontinued.
Supportive therapies, e.g. loperamide to control late-onset diarrhoea,
antibiotic therapy and transfusion, were to be given to control symp-
toms caused by treatment toxicity to the maximum possible extent.
Response and toxicity evaluation
Responses were evaluated according to the World Health
Organization (WHO) criteria (World Health Organization, 1979),
and toxicity was assessed according to JCOG Toxicity Criteria
(Tobinai et al, 1993). Since 1992, JCOG Toxicity Criteria have
been used in all clinical trials conducted by JCOG. Most detailed
gradings for individual organ toxicity in JCOG Toxicity Criteria
are identical to those of WHO Toxicity Criteria (World Health
Organization, 1979). All reported responses and toxicities were
confirmed by independent extramural review.
RESULTS
A total of 13 patients was enrolled between September 1994 and
January 1995 and efficacy and toxicity could be evaluated in 12 of
them. The remaining patient was ineligible because distant metas-
tasis was confirmed after enrolment. Table 1 shows characteristics
of the 12 eligible patients.
Table 2 shows treatment given to patients at each dose level.
Four of the six patients at level 1 completed the scheduled three
courses of chemotherapy and 60 Gy radiation therapy. One patient
discontinued chemotherapy during the second course because of
grade 3 leucopenia and grade 4 fever accompanied by hypotension
and another did so during the first course because of persistent
leucopenia. A total of 15 courses of chemotherapy was adminis-
tered to the six patients, and CPT-11 was omitted 11 times because
of leucopenia. Radiation therapy of 60 Gy was possible for all
these patients, including those who discontinued chemotherapy. In
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Table 4 Non-haematological toxicity at each dose level
JCOG toxicity criteria
Diarrhoea Oesophagitis Fever Pulmonary Skin
(grade) (grade) (grade) (grade) (grade)
Level No. of patients 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4
1 6 2 1 0 2 0 0 1 0 1 0 0 0 0 0 0
2 6 0 1 0 1 1 0 3 0 0 2 1 0 1 1 0
JCOG, Japan Clinical Oncology Group.
the light of these findings, the level 1 dose was considered toler-
able and level 2 was started.
Three ofthe six patients receiving the level 2 dose each received
three courses of chemotherapy and a total radiation dose of 56, 60
and 66 Gy. One patient refused treatment because of grade 1
nausea and vomiting and diarrhoea during the first course of
chemotherapy, another refused treatment because of persistent
abdominal pain following grade 3 diarrhoea and one patient died
of pneumonia on day 7 of the second course. The WBC count of
the latter was 9100 tl- immediately before death and autopsy
revealed no positive findings indicative oftreatment-related death.
These six patients received a total of 13 courses of level 2
chemotherapy and CPT-11 was omitted 12 times because of
leucopenia or diarrhoea. The doses of radiation given to the two
patients who refused treatment were 16 and 36 Gy, respectively,
and the patient who died had received 46 Gy.
Table 3 shows the haematological toxicity at each dose level.
Grade 3-4 leucopenia occurred at each dose level and G-CSF was
administered during 8 of 15 courses at level 1 and 10 of 13 at level
2, whereas thrombocytopenia and anaemia occurred in no patients
at level 1 and in two patients at level 2.
Table 4 shows grade 2 or greater non-haematological toxicity at
each dose level. Grade 2-3 diarrhoea occurred in three patients at
level 1 and one at level 2, and CPT-I I was omitted during two
courses because of diarrhoea. Grade 2-3 oesophagitis occurred in
two patients each at level I and 2, and radiation therapy was post-
poned I week because of grade 3 oesophagitis in one patient.
Grade 2 or greater other toxicity included fever in two patients at
level I and three at level 2, pulmonary toxicity in three at level 2
and skin reactions in two at level 2. Grade 3 pulmonary toxicity
resulted from the exacerbation ofobstructive pneumonia and there
were no positive findings indicative of a causal relationship with
CPT-11. The performance status of four patients at level 1 and
three at level 2, respectively, deteriorated to 2 from 0-1. As the
CPT- 1I dose intensity was low throughout levels I and 2 because
ofthe necessity to omit CPT- 1 administration on days 8 and/or 15
owing to leucopenia or diarrhoea, and the low radiation therapy
completion rate, this study was discontinued at level 2.
Five patients at level 1 and three at level 2 showed partial
responses, an overall response rate of67% (eight partial responses in
12 patients). Median duration ofresponse was 41 weeks. The overall
survival rates by the Kaplan-Meier method were 33% and 17% at I
and 2 years, respectively, with a median survival of45 weeks.
DISCUSSION
In the European Organization for Research and Treatment of
Cancer (EORTC) randomized trial, local tumour control and
overall survival (26% at 2 years) was improved by daily low-dose
cisplatin, and concurrent radiation therapy with acceptable
oesophageal and pulmonary toxicity (Schaake-Koning et al,
1992). In a recent randomized study in Yugoslavia, excellent
results, i.e. median survival of 22 months, a 4-year survival rate of
23% and acceptable tolerability were reported in patients receiving
a combination ofhyperfractionated radiation therapy and low-dose
daily carboplatin plus etoposide (VP-16) (Jeremic et al, 1996). It
was mentioned, however, that distant metastases were not
controlled adequately by these daily low-dose chemotherapy
regimens, which consequently are not recognized as a standard
therapeutic regimen.
Intensification ofchemotherapy during radiation has the potential
of improving both local control and metastasis-free survival. The
North Central Cancer Treatment Group (NCCTG) study reported
that the incidence of systemic failures in patients who received
twice-daily radiation therapy plus concomitant two courses of
cisplatin-VP-16 was lower than that of patients receiving standard
radiation therapy alone (McGinnis et al, 1995). In a recent random-
ized study by JCOG, concurrent radiotherapy and effective systemic
chemotherapy with mitomycin, vindesine and cisplatin yielded a
significantly increased response and a longer survival time (16.4 vs
13.3 months) than those receiving chemotherapy followed by radio-
therapy for locally advanced NSCLC (Furuse et al, 1997).
CPT- I 1, a topoisomerase I inhibitor, has single-agent activity in
NSCLC (Fukuoka et al, 1992; Douillard et al, 1995; Baker et al,
1997), and a high response rate could be produced in combination
with cisplatin (Masuda et al, 1992; Nakagawa et al, 1993; DeVore
et al, 1997). Furthermore, camptothecin analogues, topoisomerase I
inhibitors, have been reported to potentiate the radiation effect in
vitro and in vivo (Boothman et al, 1989; Falk et al, 1992; Kim et al,
1992; Tamura et al, 1997). However, the optimal timing oftopoiso-
merase I inhibitor treatment (pre-, concurrent, post-irradiation) for
maximizing the radiosensitizing effect remains controversial. In the
present study, we attempted both to improve local control and to
reduce distant failures by combining standard fractionation radio-
therapy and effective systemic chemotherapy with CPT-11 and
cisplatin. As the clinical interactions of this combined-modality
therapy have not been described previously, we initiated the dose-
finding study against unresectable stage III NSCLC.
At dose level 1, four of six patients tolerated the combined
chemoradiation therapy and five of the six responded to this
regimen. The frequency and grade of toxicities did not reach the
criteria of maximum tolerated dose, so we escalated the dose to
level 2. At level 2, two patients refused treatment, one because of
the dose-limiting toxicity of the regimen, and one died early.
Throughout levels I and 2, the CPT-11 dose intensity was lower
than planned, 72% and 63%, respectively, and performance status
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decreased in 7 of 12 patients. Leucopenia was the principal myelo-
toxic adverse effect in this study. G-CSF was used with 53% of
level 1 courses and 77% of level 2 courses. CPT-11 was omitted
frequently on days 8 and/or 15 because of leucopenia. Thus, the
CPT- 11 dose intensity was clearly lower than that reported in
another study of combined CPT-11 and cisplatin (Masuda et al,
1992). It was suggested that leucopenia may be a dose-limiting
toxicity. Although diarrhoea was not necessarily a dose-limiting
toxicity, this symptom is considered to be an adverse reaction that
reduces the performance status of patients. Potentiation of
pulmonary toxicity is a frequent concern during combined
chemoradiotherapy (Reckzeh et al, 1996). The incidence of this
adverse reaction in association with CPT-11 alone was reported to
be 6% (Fukuoka et al, 1992). In this study, interstitial pneumonia
did not occur in areas outside those irradiated. However, patients
receiving CPT-11 chemotherapy with concurrent radiation therapy
should be monitored carefully for interstitial pneumonia, as only a
few patients have received this combination and few data have
been accumulated so far. Approximately halfthe patients receiving
a combination of paclitaxel, cisplatin and VP-16 and concurrent
radiation therapy were reported to have experienced grade 3 or 4
oesophagitis, but this combination was feasible and highly active
(Greco et al, 1996). Oesophagitis is the most common adverse
effect potentiated by concurrent chemoradiotherapy. The severity
ofoesophagitis was acceptable in our present study.
In net respect, the compliance and dose intensity of this
combined modality were not satisfactory. We therefore concluded
that both dose levels were unacceptable for further investigation.
In conclusion, although the maximum tolerated dose could not be
identified in this study with CPT-11, cisplatin and concurrent
conventional radiation therapy, toxicity was not considered accept-
able and leucopenia appeared to be the dose-limiting toxicity. In
future studies, the tolerability, toxicity and efficacy ofCPT-11 as a
single agent in combination with radiation therapy need to be
examined. At present, two phase I/II studies examining weekly
schedules of CPT-11 with concurrent conventional radiation
therapy are in progress.
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